ADVITOS GMBH

Their core work

ADVITOS is a Munich-based medical device SME that developed and commercializes the ADVOS (ADVanced Organ Support) system — an extracorporeal hemodialysis technology designed to support liver, kidney and acid-base functions simultaneously in intensive care patients with multiple organ failure. Their core product is used in ICUs to treat critically ill patients for whom conventional dialysis is insufficient. The company focuses on clinical validation, market access and health-economics evidence for this specialized therapy. Their work sits at the intersection of biomedical engineering and critical care medicine.

What they specialise in

How they've shifted over time

With only two H2020 projects, evolution is limited but directional. The 2019 ADVOS grant funded broad commercialization of the multi-organ support platform, while the 2020 ADVOS-COVID-19 grant pivoted the same technology to address the pandemic emergency — specifically multi-organ failure in severe SARS-CoV-2 patients. The trajectory shows a company expanding clinical indications of a single core device rather than diversifying its technology base.

Likely continuing to broaden clinical indications of the ADVOS platform (sepsis, post-viral, hepatorenal syndrome) and building health-economics evidence for reimbursement in European ICUs.

How they like to work

ADVITOS coordinated both H2020 projects under the single-beneficiary SME Instrument, so no consortium partners appear in the dataset. This is the classic product-focused medtech SME profile: EU funding used to accelerate commercialization of a proprietary device rather than to build research networks. Useful partners are typically clinical sites, distributors and complementary medtech firms rather than co-developers.

No formal H2020 consortium network is visible — both projects are solo SME-Instrument grants. Clinical and commercial partnerships exist outside the CORDIS dataset.

What sets them apart

ADVITOS owns a rare piece of medical technology — a single extracorporeal device that simultaneously supports liver, kidney and acid-base balance functions for ICU patients who fail conventional dialysis. Few European SMEs hold a comparable proprietary multi-organ support platform validated through the EU SME Instrument. For a partner, the value is access to a commercialized device with pandemic-era clinical evidence, not a research collaboration.

Highlights from their portfolio

• ADVOS
  Their flagship EUR 2.29M SME-2 grant (2019-2022) funded commercialization of the ADVanced Organ Support system — the company's core product.
• ADVOS-COVID-19
  A rapid pandemic pivot (2020-2023) extending ADVOS to severe SARS-CoV-2 patients with multi-organ failure, backed by health-economics evidence.